Journal
BLOOD CANCER JOURNAL
Volume 5, Issue -, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/bcj.2015.20
Keywords
-
Categories
Funding
- Mayo Clinic Hematological Malignancies Program
- Paul Calabresi K12 Award [CA96028]
- National Cancer Institute, Rockville, MD, USA [CA 107476, CA 62242, CA100707, CA 83724]
- CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 TR000135]
Ask authors/readers for more resources
Renal impairment (RI) is seen in over a quarter of patients with newly diagnosed multiple myeloma (NDMM). It is not clear if reversal of RI improves the outcome to that expected for NDMM patients without RI. We evaluated 1135 consecutive patients with NDMM seen at the Mayo Clinic between January 2003 and December 2012. RI was defined as having a creatinine clearance (CrCl) <40ml/min. The median overall survival (OS) for patients with RI at diagnosis receiving and not receiving novel agent induction therapy was not reached vs 46 months (P<0.001). The median OS for patients with CrCl >= 40 ml/min at diagnosis, CrCl <40 ml/min at diagnosis but improved to >= 40 ml/min and CrCl <40 ml/min at diagnosis and remained <40 ml/min, were 112, 56 and 33 months, respectively (P<0.001). The complete renal response rate for patients with RI at diagnosis receiving novel agent induction therapy compared to the rest was 40 vs 16% (P<0.001). In conclusion, patients with reversal of RI have improved outcomes, but it remains inferior to patients with normal renal function at diagnosis. These results have implications for identifying early treatment strategies for patients at risk of developing renal insufficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available